Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

mTOR inhibitors for treatment of low-risk prostate cancer.

Liss MA, Rickborn L, DiGiovanni J, Bacich D, DeGraffenried LA, Parihar M, Thompson IM, Sharp ZD.

Med Hypotheses. 2018 Aug;117:63-68. doi: 10.1016/j.mehy.2018.06.004. Epub 2018 Jun 5.

2.

Leptin Signaling Mediates Obesity-Associated CSC Enrichment and EMT in Preclinical TNBC Models.

Bowers LW, Rossi EL, McDonell SB, Doerstling SS, Khatib SA, Lineberger CG, Albright JE, Tang X, deGraffenried LA, Hursting SD.

Mol Cancer Res. 2018 May;16(5):869-879. doi: 10.1158/1541-7786.MCR-17-0508. Epub 2018 Feb 16.

3.

Effects of Obesity on the Regulation of Macrophage Population in the Prostate Tumor Microenvironment.

Galván GC, Johnson CB, Price RS, Liss MA, Jolly CA, deGraffenried LA.

Nutr Cancer. 2017 Oct;69(7):996-1002. doi: 10.1080/01635581.2017.1359320. Epub 2017 Sep 25.

PMID:
28945110
4.

Energy Balance Modulation Impacts Epigenetic Reprogramming, ERα and ERβ Expression, and Mammary Tumor Development in MMTV-neu Transgenic Mice.

Rossi EL, Dunlap SM, Bowers LW, Khatib SA, Doerstling SS, Smith LA, Ford NA, Holley D, Brown PH, Estecio MR, Kusewitt DF, deGraffenried LA, Bultman SJ, Hursting SD.

Cancer Res. 2017 May 1;77(9):2500-2511. doi: 10.1158/0008-5472.CAN-16-2795. Epub 2017 Apr 3.

5.

Breast Cancer Genetic and Molecular Subtype Impacts Response to Omega-3 Fatty Acid Ethyl Esters.

Chen CH, Fabian C, Hursting S, deGraffenried LA.

Nutr Cancer. 2016 Aug-Sep;68(6):1021-33. doi: 10.1080/01635581.2016.1192199. Epub 2016 Jul 1.

PMID:
27367296
6.

Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.

Bowers LW, Wiese M, Brenner AJ, Rossi EL, Tekmal RR, Hursting SD, deGraffenried LA.

PLoS One. 2015 Dec 28;10(12):e0145452. doi: 10.1371/journal.pone.0145452. eCollection 2015.

7.

Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population.

Bowers LW, deGraffenried LA.

Curr Pharmacol Rep. 2015 Oct 1;1(5):336-345. Epub 2015 Apr 22.

8.

Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer.

Ford NA, Rossi EL, Barnett K, Yang P, Bowers LW, Hidaka BH, Kimler BF, Carlson SE, Shureiqi I, deGraffenried LA, Fabian CJ, Hursting SD.

Cancer Prev Res (Phila). 2015 Sep;8(9):796-806. doi: 10.1158/1940-6207.CAPR-15-0018. Epub 2015 Jun 22.

9.

The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.

Bowers LW, Rossi EL, O'Flanagan CH, deGraffenried LA, Hursting SD.

Front Endocrinol (Lausanne). 2015 May 15;6:77. doi: 10.3389/fendo.2015.00077. eCollection 2015. Review.

10.

Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production.

Bowers LW, Brenner AJ, Hursting SD, Tekmal RR, deGraffenried LA.

Breast Cancer Res Treat. 2015 Jan;149(1):49-57. doi: 10.1007/s10549-014-3223-0. Epub 2014 Dec 5.

11.

Obesity promotes aerobic glycolysis in prostate cancer cells.

Cavazos DA, deGraffenried MJ, Apte SA, Bowers LW, Whelan KA, deGraffenried LA.

Nutr Cancer. 2014;66(7):1179-86. doi: 10.1080/01635581.2014.951738. Epub 2014 Sep 29.

12.

NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.

Bowers LW, Maximo IX, Brenner AJ, Beeram M, Hursting SD, Price RS, Tekmal RR, Jolly CA, deGraffenried LA.

Cancer Res. 2014 Aug 15;74(16):4446-57. doi: 10.1158/0008-5472.CAN-13-3603.

13.

Mitochondrial glycerol-3-phosphate acyltransferase-1 is essential for murine CD4(+) T cell metabolic activation.

Faris R, Fan YY, De Angulo A, Chapkin RS, deGraffenried LA, Jolly CA.

Biochim Biophys Acta. 2014 Oct;1842(10):1475-82. doi: 10.1016/j.bbalip.2014.07.009. Epub 2014 Jul 24.

14.

Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.

Bowers LW, Cavazos DA, Maximo IX, Brenner AJ, Hursting SD, deGraffenried LA.

Breast Cancer Res. 2013;15(4):R59.

15.

A low dietary ratio of omega-6 to omega-3 Fatty acids may delay progression of prostate cancer.

Apte SA, Cavazos DA, Whelan KA, Degraffenried LA.

Nutr Cancer. 2013;65(4):556-62. doi: 10.1080/01635581.2013.775316.

PMID:
23659447
16.

Anethole suppressed cell survival and induced apoptosis in human breast cancer cells independent of estrogen receptor status.

Chen CH, deGraffenried LA.

Phytomedicine. 2012 Jun 15;19(8-9):763-7. doi: 10.1016/j.phymed.2012.02.017. Epub 2012 Mar 30.

PMID:
22464689
17.

Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells.

Price RS, Cavazos DA, De Angel RE, Hursting SD, deGraffenried LA.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):135-43. doi: 10.1038/pcan.2011.54. Epub 2012 Feb 14.

PMID:
22333686
18.

The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.

De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, Hursting SD.

Mol Carcinog. 2013 Jun;52(6):446-58. doi: 10.1002/mc.21878. Epub 2012 Jan 30.

PMID:
22290600
19.

Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.

Tiwary R, Yu W, deGraffenried LA, Sanders BG, Kline K.

Breast Cancer Res. 2011;13(6):R120. doi: 10.1186/bcr3063. Epub 2011 Nov 24.

20.

Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF-κB.

Cavazos DA, Price RS, Apte SS, deGraffenried LA.

Prostate. 2011 Sep 15;71(13):1420-8. doi: 10.1002/pros.21359. Epub 2011 Feb 25.

PMID:
21360560
21.

Label-retaining cells of the bladder: candidate urothelial stem cells.

Kurzrock EA, Lieu DK, Degraffenried LA, Chan CW, Isseroff RR.

Am J Physiol Renal Physiol. 2008 Jun;294(6):F1415-21. doi: 10.1152/ajprenal.00533.2007. Epub 2008 Mar 26.

22.

Characterization of PacMetUT1, a recently isolated human prostate cancer cell line.

Troyer DA, Tang Y, Bedolla R, Adhvaryu SG, Thompson IM, Abboud-Werner S, Sun LZ, Friedrichs WE, deGraffenried LA.

Prostate. 2008 Jun 1;68(8):883-92. doi: 10.1002/pros.20758.

PMID:
18361412
23.

Akt-induced tamoxifen resistance is associated with altered FKHR regulation.

Silva J, Cavazos DA, Donzis E, Friedrichs WE, Marciniak R, deGraffenried LA.

Cancer Invest. 2007;25(7):569-73.

PMID:
17952739
24.

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.

Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA.

Ann Oncol. 2007 Aug;18(8):1323-8.

PMID:
17693645
25.

Beta1 integrin expression pattern in transitional urothelium does not allow for efficient stem cell enrichment as in other epithelia.

Lieu DK, Degraffenried LA, Isseroff RR, Kurzrock EA.

Tissue Eng. 2007 Feb;13(2):263-70.

PMID:
17518562
26.

Urothelial progenitor cells: regional differences in the rat bladder.

Nguyen MM, Lieu DK, deGraffenried LA, Isseroff RR, Kurzrock EA.

Cell Prolif. 2007 Apr;40(2):157-65.

PMID:
17472724
27.

Rat urothelium: improved techniques for serial cultivation, expansion, freezing and reconstitution onto acellular matrix.

Kurzrock EA, Lieu DK, deGraffenried LA, Isseroff RR.

J Urol. 2005 Jan;173(1):281-5.

PMID:
15592097
28.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

29.

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.

DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M.

Ann Oncol. 2004 Oct;15(10):1510-6.

PMID:
15367412
30.

NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen.

deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR.

Ann Oncol. 2004 Jun;15(6):885-90.

PMID:
15151944
31.

Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha.

deGraffenried LA, Hopp TA, Valente AJ, Clark RA, Fuqua SA.

Breast Cancer Res Treat. 2004 May;85(2):111-20.

PMID:
15111769
32.

Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity.

DeGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, Peralba JM, Hidalgo M.

Ann Oncol. 2003 Jul;14(7):1051-6.

PMID:
12853346
33.

Sp1 is essential for estrogen receptor alpha gene transcription.

deGraffenried LA, Hilsenbeck SG, Fuqua SA.

J Steroid Biochem Mol Biol. 2002 Sep;82(1):7-18.

PMID:
12429135
34.

Wound dressings alter the colony-forming efficiency of keratinocytes in cultured sheet grafts.

deGraffenried LA, Isseroff RR.

Cell Transplant. 2001;10(8):749-54.

PMID:
11814118
35.

Modulation of human epidermal cell response to 2,3,7,8-tetrachlorodibenzo-p-dioxin by epidermal growth factor.

Rea MA, Phillips MA, Degraffenried LA, Qin Q, Rice RH.

Carcinogenesis. 1998 Mar;19(3):479-83.

PMID:
9525283
36.

Anti-proliferative activity and target cell catabolism of the vitamin D analog 1 alpha,24(S)-(OH)2D2 in normal and immortalized human epidermal cells.

Jones G, Byford V, Makin HL, Kremer R, Rice RH, deGraffenried LA, Knutson JC, Bishop CW.

Biochem Pharmacol. 1996 Jul 12;52(1):133-40.

PMID:
8678897
37.

Cell type-specific and inflammatory-induced expression of haptoglobin gene in lung.

Yang F, Friedrichs WE, Navarijo-Ashbaugh AL, deGraffenried LA, Bowman BH, Coalson JJ.

Lab Invest. 1995 Sep;73(3):433-40.

PMID:
7564277
38.
39.

Predictive value of liver slices for metabolism and toxicity in vivo: use of acetaminophen as a model hepatotoxicant.

Miller MG, Beyer J, Hall GL, deGraffenried LA, Adams PE.

Toxicol Appl Pharmacol. 1993 Sep;122(1):108-16.

PMID:
8378925
40.

Elevation of cell cycle control proteins during spontaneous immortalization of human keratinocytes.

Rice RH, Steinmann KE, deGraffenried LA, Qin Q, Taylor N, Schlegel R.

Mol Biol Cell. 1993 Feb;4(2):185-94.

Supplemental Content

Loading ...
Support Center